Poorly Differentiated Lung Adenocarcinoma Without Recurrence After Surgery and Chemotherapy
This lung cancer diagnosis at a glance
- Subtype
- Adenocarcinoma
- Biomarkers
- No driver mutation identified; PD-L1 at least 1%
- Sex
- male
- Treatment
- surgery and chemotherapy
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- Underwent right upper lobectomy with systematic mediastinal lymph-node dissection in August 2024.
- One month later, received 4 cycles of carboplatin and pemetrexed.
What happened, in summary
A 65-year-old man was evaluated after an accidental injury in August 2024, when chest imaging unexpectedly found a 3 cm mass in the right upper lung with involvement of hilar lymph nodes. He had a heavy smoking history but no abnormalities on head or abdominal imaging.
He underwent a right upper lobectomy with systematic mediastinal lymph-node dissection. Pathology showed poorly differentiated lung adenocarcinoma. The tumor had loss of SMARCA2 expression while SMARCA4 was preserved. Genomic testing did not identify a driver mutation, and PD-L1 expression was at least 1%.
One month after surgery, he began adjuvant carboplatin and pemetrexed and completed 4 cycles. Through April 2025, follow-up had found no signs of recurrence. His case was presented alongside another patient with the same rare molecular pattern to explore why SMARCA2-deficient lung adenocarcinoma may behave aggressively in some people despite preserved SMARCA4 expression.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Carboplatin for Lung Cancer 168 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer